Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -96.97% is 83% below its 5-year average of -53.13%, near the low end of its 5-year range (-122.52%–-27.79%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.42% below its 12-month average of -88.62%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -96.97%.
RETURN ON EQUITY (ROE)
-96.97%
RETURN ON EQUITY (ROE) AVG TTM
-88.62%
RETURN ON EQUITY (ROE) AVG 3Y
-61.26%
RETURN ON EQUITY (ROE) AVG 5Y
-53.13%
RETURN ON EQUITY (ROE) AVG 10Y
-55.08%
RETURN ON EQUITY (ROE) AVG 15Y
-52.44%
RETURN ON EQUITY (ROE) AVG 20Y
-55.67%
CURRENT VS TTM AVG
-9.42%
CURRENT VS 3Y AVG
-58.29%
CURRENT VS 5Y AVG
-82.52%
CURRENT VS 10Y AVG
-76.06%
CURRENT VS 15Y AVG
-84.93%
CURRENT VS 20Y AVG
-74.20%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-130.83%
vs the sector median at left
Savara Inc.
Market Cap
$959.06M
Return on Equity (ROE)
-96.97%
TTM Avg
-88.62%
3Y Avg
-61.26%
5Y Avg
-53.13%
Market Cap
$952.79M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$970.71M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$943.21M
Return on Equity (ROE)
N/A
TTM Avg
80.91%
3Y Avg
80.91%
5Y Avg
80.91%
Market Cap
$977.08M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$980.66M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$980.55M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$991.24M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
Market Cap
$926.80M
Return on Equity (ROE)
-612.78%
TTM Avg
-101.05%
3Y Avg
-68.21%
5Y Avg
-52.21%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $959.06M | -96.97% | -88.62% | -61.26% | -53.13% |
| Aktis Oncology, Inc. (AKTS)vs › | $952.79M | -15.09% | 46.85% | 62.20% | 62.20% |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.71M | 2.18% | -5.89% | -1.23% | 4.05% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $943.21M | N/A | 80.91% | 80.91% | 80.91% |
| MeiraGTx Holdings plc (MGTX)vs › | $977.08M | 36.64% | 876.73% | 395.64% | 252.56% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $980.66M | -25.78% | 29.18% | 31.59% | 31.59% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $980.55M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.24M | -32.27% | -24.43% | -32.70% | -40.03% |
| Kura Oncology, Inc. (KURA)vs › | $926.80M | -612.78% | -101.05% | -68.21% | -52.21% |
| MoonLake Immunotherapeutics (MLTX)vs › | $923.17M | -61.58% | -50.64% | -52.69% | 41.64% |
ROE
-97.0%
ROA
-72.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -96.97% |
| 2026-03-31 | -73.55% |
| 2025-12-31 | -58.50% |
| 2025-09-30 | -122.52% |
| 2025-06-30 | -91.57% |
| 2025-03-31 | -69.11% |
| 2024-12-31 | -55.92% |
| 2024-09-30 | -41.60% |
| 2024-06-30 | -74.01% |
| 2024-03-31 | -52.92% |
| 2023-12-31 | -38.97% |
| 2023-09-30 | -33.37% |
| 2023-06-30 | -48.66% |
| 2023-03-31 | -41.12% |
| 2022-12-31 | -35.40% |
| 2022-09-30 | -33.61% |
| 2022-06-30 | -30.95% |
| 2022-03-31 | -30.11% |
| 2021-12-31 | -29.77% |
| 2021-09-30 | -29.28% |
| 2021-06-30 | -27.79% |
| 2021-03-31 | -25.36% |
| 2020-12-31 | -77.06% |
| 2020-09-30 | -88.21% |
| 2020-06-30 | -82.26% |
| 2020-03-31 | -93.32% |
| 2019-12-31 | -76.87% |
| 2019-09-30 | -53.34% |
| 2019-06-30 | -50.64% |
| 2019-03-31 | -45.95% |
| 2018-12-31 | -56.84% |
| 2018-09-30 | -48.79% |
| 2018-06-30 | -62.58% |
| 2018-03-31 | -55.14% |
| 2017-12-31 | -25.72% |
| 2017-09-30 | -40.49% |
| 2017-06-30 | -39.56% |
| 2017-03-31 | -707.17% |
| 2016-09-30 | -305.06% |
| 2016-06-30 | -255.62% |
| 2016-03-31 | -200.35% |
| 2015-12-31 | -166.78% |
| 2015-09-30 | -110.30% |
| 2015-06-30 | -82.16% |
| 2015-03-31 | -63.76% |
| 2014-12-31 | -48.93% |
| 2014-09-30 | -59.88% |
| 2014-06-30 | -48.75% |
| 2014-03-31 | -42.19% |
| 2013-12-31 | -44.93% |
| 2013-09-30 | -37.26% |
| 2013-06-30 | -30.60% |
| 2013-03-31 | -46.47% |
| 2012-12-31 | -37.23% |
| 2012-09-30 | -30.10% |
| 2012-06-30 | -29.09% |
| 2012-03-31 | -27.30% |
| 2011-12-31 | -23.35% |
| 2011-09-30 | -40.54% |
| 2011-06-30 | -43.37% |
| 2011-03-31 | -44.74% |
| 2010-12-31 | -73.07% |
| 2010-09-30 | -55.97% |
| 2010-06-30 | -40.35% |
| 2010-03-31 | -56.15% |
| 2009-12-31 | -169.70% |
| 2009-09-30 | -961.18% |
| 2009-06-30 | -872.95% |
| 2009-03-31 | -792.50% |
| 2008-12-31 | -444.48% |
| 2008-09-30 | -184.92% |
| 2008-06-30 | -120.28% |
| 2008-03-31 | -89.13% |
| 2007-12-31 | -71.35% |
| 2007-09-30 | -64.63% |
| 2007-06-30 | -53.72% |
| 2007-03-31 | -29.27% |
| 2006-12-31 | -146.97% |
| 2005-09-30 | -48.45% |
| 2005-06-30 | -136.45% |
| 2005-03-31 | -90.19% |
| 2004-12-31 | -54.08% |
| 2004-09-30 | -35.22% |
| 2004-06-30 | -21.39% |
| 2004-03-31 | -73.85% |
| 2003-12-31 | -56.59% |
| 2003-09-30 | -45.16% |
| 2003-06-30 | -145.88% |
